Adebrelimab combo for platinum-sensitive relapsed ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), a targeted therapy (bevacizumab), and a PARP inhibitor (fluzoparib) for ovarian cancer that came back at least 6 months after last platinum chemo. It aims to see if this mix helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that came back at least 6 months after finishing platinum chemo
- You have had no more than 2 prior chemo treatments for your cancer
- You have not taken a PARP inhibitor more than once before
- You do not have a BRCA gene mutation (germline)
- You are in fairly good health (ECOG score 0 or 1) and have at least one tumor that can be measured on scans
- You are between 18 and 75 years old and willing to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for ovarian cancer that has come back quickly after platinum-based chemo. The goal is to see if adding an immunotherapy and a targeted pill to non-platinum chemo can help shrink tumors.
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
This trial tests a new combination of drugs—QL1706 (which targets two immune checkpoints), nab-paclitaxel, and bevacizumab—for people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
Hear when a new Platinum-sensitive Relapsed Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.